|
1
|
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
|
J Natl Cancer Inst
|
2006
|
14.60
|
|
2
|
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
|
Clin Cancer Res
|
2007
|
8.41
|
|
3
|
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
|
J Natl Cancer Inst
|
2006
|
8.38
|
|
4
|
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
|
Lancet
|
2011
|
4.73
|
|
5
|
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
|
J Clin Oncol
|
2009
|
4.05
|
|
6
|
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
|
Nat Clin Pract Oncol
|
2006
|
2.84
|
|
7
|
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
|
J Clin Oncol
|
2005
|
2.70
|
|
8
|
Multidisciplinary meeting on male breast cancer: summary and research recommendations.
|
J Clin Oncol
|
2010
|
2.53
|
|
9
|
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
|
J Natl Cancer Inst
|
2010
|
2.28
|
|
10
|
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
|
Lancet Oncol
|
2011
|
2.01
|
|
11
|
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
|
Breast Cancer Res Treat
|
2008
|
1.96
|
|
12
|
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
|
Eur J Cancer
|
2011
|
1.79
|
|
13
|
Comparison of prognostic gene expression signatures for breast cancer.
|
BMC Genomics
|
2008
|
1.71
|
|
14
|
Multifactorial approach to predicting resistance to anthracyclines.
|
J Clin Oncol
|
2011
|
1.52
|
|
15
|
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
|
J Clin Oncol
|
2008
|
1.50
|
|
16
|
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
|
J Clin Oncol
|
2013
|
1.45
|
|
17
|
Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
|
Cancer Genomics Proteomics
|
2007
|
1.38
|
|
18
|
Facts and controversies in systemic treatment of metastatic breast cancer.
|
Oncologist
|
2004
|
1.37
|
|
19
|
Breast cancer in pregnancy: recommendations of an international consensus meeting.
|
Eur J Cancer
|
2010
|
1.31
|
|
20
|
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
|
Eur J Cancer
|
2007
|
1.31
|
|
21
|
International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.
|
Breast
|
2013
|
1.31
|
|
22
|
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
|
Mol Cancer Ther
|
2004
|
1.17
|
|
23
|
Stemming resistance to HER-2 targeted therapy.
|
J Mammary Gland Biol Neoplasia
|
2009
|
1.14
|
|
24
|
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.13
|
|
25
|
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
|
Clin Cancer Res
|
2005
|
1.13
|
|
26
|
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
|
Clin Breast Cancer
|
2002
|
1.11
|
|
27
|
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
|
Breast
|
2010
|
1.09
|
|
28
|
An update on male breast cancer and future directions for research and treatment.
|
Eur J Pharmacol
|
2013
|
1.06
|
|
29
|
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
|
Clin Cancer Res
|
2008
|
1.02
|
|
30
|
Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools.
|
BMC Genomics
|
2007
|
1.01
|
|
31
|
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
|
Breast Cancer Res Treat
|
2010
|
1.00
|
|
32
|
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
|
Curr Cancer Drug Targets
|
2009
|
0.98
|
|
33
|
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
|
Breast Cancer Res Treat
|
2010
|
0.97
|
|
34
|
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
|
Oncologist
|
2006
|
0.96
|
|
35
|
Molecular targeted therapies in breast cancer: where are we now?
|
Int J Biochem Cell Biol
|
2007
|
0.96
|
|
36
|
Tamoxifen therapy for patients with breast cancer.
|
Lancet
|
2013
|
0.96
|
|
37
|
Bringing molecular prognosis and prediction to the clinic.
|
Clin Breast Cancer
|
2005
|
0.95
|
|
38
|
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
|
Nat Rev Clin Oncol
|
2011
|
0.94
|
|
39
|
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
|
Eur J Cancer
|
2007
|
0.94
|
|
40
|
Molecular forecasting of breast cancer: time to move forward with clinical testing.
|
J Clin Oncol
|
2006
|
0.94
|
|
41
|
Time for more optimism in metastatic breast cancer?
|
Cancer Treat Rev
|
2013
|
0.93
|
|
42
|
Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
|
J Clin Oncol
|
2008
|
0.92
|
|
43
|
Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative.
|
Breast
|
2011
|
0.91
|
|
44
|
Facts and controversies in the use of trastuzumab in the adjuvant setting.
|
Nat Clin Pract Oncol
|
2008
|
0.91
|
|
45
|
Metastatic breast cancer patients: the forgotten heroes!
|
Breast
|
2009
|
0.91
|
|
46
|
What clinicians need to know about antioestrogen resistance in breast cancer therapy.
|
Eur J Cancer
|
2006
|
0.89
|
|
47
|
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
|
Oncologist
|
2014
|
0.89
|
|
48
|
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.
|
Int J Clin Oncol
|
2002
|
0.88
|
|
49
|
Challenges in breast cancer clinical trial design in the postgenomic era.
|
Curr Opin Oncol
|
2004
|
0.86
|
|
50
|
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
|
Oncologist
|
2007
|
0.85
|
|
51
|
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
|
Semin Oncol
|
2005
|
0.84
|
|
52
|
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.
|
Breast Cancer Res Treat
|
2002
|
0.83
|
|
53
|
Breast cancer gene expression profiling: clinical trial and practice implications.
|
Pharmacogenomics
|
2005
|
0.81
|
|
54
|
A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.80
|
|
55
|
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
|
Breast
|
2012
|
0.79
|
|
56
|
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
|
Invest New Drugs
|
2010
|
0.79
|
|
57
|
Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials.
|
Breast
|
2013
|
0.77
|
|
58
|
Corrigendum: Management of locally advanced breast cancer--perspectives and future directions.
|
Nat Rev Clin Oncol
|
2015
|
0.77
|
|
59
|
Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
|
Crit Care Med
|
2009
|
0.77
|
|
60
|
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
|
Breast Cancer Res
|
2009
|
0.77
|
|
61
|
HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
|
Anticancer Res
|
2002
|
0.76
|
|
62
|
MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.
|
Expert Opin Med Diagn
|
2009
|
0.76
|
|
63
|
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
|
J Clin Oncol
|
2006
|
0.75
|
|
64
|
ASCO 2009: What's New in Breast Cancer Therapy?
|
Breast Care (Basel)
|
2009
|
0.75
|
|
65
|
Sunitinib in breast cancer: friend or foe.
|
Breast
|
2009
|
0.75
|
|
66
|
Neoadjuvant endocrine therapy: for whom, for how long?
|
Clin Transl Oncol
|
2012
|
0.75
|
|
67
|
3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
|
Anticancer Res
|
2002
|
0.75
|
|
68
|
New tools for assessing breast cancer recurrence.
|
Cancer Treat Res
|
2008
|
0.75
|
|
69
|
The voice of youth.
|
Eur J Cancer
|
2006
|
0.75
|
|
70
|
[The new generation of breast cancer clinical trials: the right drug for the right target].
|
Bull Cancer
|
2008
|
0.75
|
|
71
|
[News in the medical treatment of breast cancer].
|
Bull Cancer
|
2003
|
0.75
|
|
72
|
Performance of compost filtration practice for green infrastructure stormwater applications.
|
Water Environ Res
|
2013
|
0.75
|